Literature DB >> 19505842

The role of bone marrow cells for JCV pathogenicity.

Daniele Focosi, Fabrizio Maggi, Elisabetta Andreoli, Letizia Lanini, Luca Ceccherini-Nelli, Mario Petrini.   

Abstract

Mesh：

Year:  2009        PMID： 19505842     DOI： 10.1016/j.jcv.2009.05.023

Source DB:  PubMed          Journal:  J Clin Virol        ISSN： 1386-6532            Impact factor:   3.168


× No keyword cloud information.
  3 in total

1.  Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab.

Authors:  Simone Giannecchini; Valeria Clausi; Alessandra Vultaggio; Lisa Macera; Fabrizio Maggi; Francesco Martelli; Alberta Azzi; Enrico Maggi; Andrea Matucci
Journal:  J Neurovirol       Date:  2012-01-27       Impact factor: 2.643

2.  No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan.

Authors:  D Focosi; L Macera; E Ciabatti; S Galimberti; M Petrini; A M Carella; M Pistello; L Ceccherini-Nelli; F Maggi
Journal:  Infection       Date:  2014-08-21       Impact factor: 3.553

3.  Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier.

Authors:  Moti L Chapagain; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.